Assessing BRCA carrier probabilities in extended families

Journal of Clinical Oncology

Volumn 24, Issue 3, 2006, Pages 354-360

  Barcenas, Carlos H ^a   Hosain, G M Monawar ^a   Arun, Banu ^a   Zong, Jihong ^a   Zhou, Xiaojun ^a   Chen, Jianfang ^a   Cortada, Jill M ^a   Mills, Gordon B ^a   Tomlinson, Gail E ^a   Miller, Alexander R ^a   Strong, Louise C ^a   Amos, Christopher I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; EXTENDED FAMILY; FEMALE; GENE MUTATION; HETEROZYGOTE DETECTION; HUMAN; INTERMETHOD COMPARISON; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVARY CANCER; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ADULT; AGED; BREAST TUMOR; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HETEROZYGOTE; JEW; METHODOLOGY; MIDDLE AGED; MUTATION; PEDIGREE; RETROSPECTIVE STUDY; ROC CURVE; STATISTICAL MODEL; STATISTICS; TUMOR SUPPRESSOR GENE; UNITED STATES;

ADULT; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HETEROZYGOTE; HUMANS; JEWS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MUTATION; PEDIGREE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; TEXAS;

EID: 33644844013     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.2368     Document Type: Article

References (27)

1. Narod SA, Foulkes WD: BRCA1 and BRCA2 1994 and beyond. Nat Rev Cancer 4:665-676, 2004
2. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003
3. Narod SA: Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2:113-123, 2002
4. Rebbeck TR, Friebel T, Lynch HT, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22:1055-1062, 2004
5. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
6. King MC, Wieand S, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 286:2251-2256, 2001
7. Narod SA, Offit K: Prevention and management of hereditary breast cancer. J Clin Oncol 23:1656-1663, 2005
8. Antoniou AC, Pharoah PPD, Smith P, et al: The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91:1580-1590, 2004
9. Antoniou AC, Pharoah PDP, McMullan G, et al: A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 86:76-83, 2002
10. Parmigiani G, Berry DA, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158, 1998
11. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701-2712, 2002
12. Evans DGR, Eccles DM, Rahman N, et al: A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41:474-480, 2004
13. Evans DGR, Lalloo F, Wallace A, et al: Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 42:e39, 2005
14. Goldgar DE, Easton DF, Deffenbaugh AM, et al: Integrated evaluation of DNA sequence variants of unknown clinical significance: Application to BRCA1 and BRCA2 - Breast Cancer Information Core (BIC) Steering Committee. Am J Hum Genet 75:535-544, 2004
15. Lovelock PK, Healey S, Au W, et al: Genetic, functional and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 10.1136/jmg.2005.033258 (published online, June 2, 2005)
16. Hartge P, Struewing JP, Wacholder S, et al: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963-970, 1999
17. Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415, 1997
18. Shattuck-Eidens D, Oliphant A, McClure M, et al: BRCA1 sequence analysis in women at high risk for susceptibility mutations: Risk factor analysis and implications for genetic testing. JAMA 278:1242-1250, 1997
19. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002
20. American Society of Clinical Oncology: Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996
21. American Society of Clinical Oncology: American Society of Clinical Oncology Policy Statement: Genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406, 2003
22. Euhus DM, Smith KC, Robinson L, et al: Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 94:844-851, 2002
23. Marroni F, Aretini P, D'Andrea E, et al: Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 41:278-285, 2004
24. Phelan CM, Kwan E, Jack E, et al: A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 20:352-357, 2002
25. Kauff ND, Perez-Segura P, Robson ME, et al: Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39:611-614, 2002
26. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002
27. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214-221, 2003